scholarly journals 196 Did the cervical cytology screening during pregnancy improve their obstetric and oncologic outcomes of cervical cancer?: A retrospective study

2020 ◽  
Author(s):  
H Yamazaki ◽  
S Mitamura ◽  
K Ihira ◽  
H Watari
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Cervical Cytology ◽  
Oncologic Outcomes ◽  
Cytology Screening

Cervical Cancer Screening Clinical Practice Guidelines in Oncology

2004 ◽  
Vol 2 (6) ◽  
pp. 570 ◽  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Current Method ◽  
The United States ◽  
Cervical Cytology ◽  
Screening Guidelines ◽  
Incidence And Mortality ◽  
Recent Version ◽  
Cytology Screening

Despite a significant decrease in the incidence and mortality of cervical carcinoma in the United States, 10,520 women are expected to develop the disease in 2004, with 3,900 expected deaths. Because cervical cytology screening is the current method for early detection of this neoplasm, the purpose of the NCCN Cervical Cancer Screening Guidelines is to provide direction for the evaluation and management of cervical cytology. For the most recent version of the guidelines, please visit NCCN.org

Screening for Cervical Cancer in Low-Resource Settings in 2011

2013 ◽  
Vol 137 (6) ◽  
pp. 782-790 ◽  
Author(s):  
Rosemary Tambouret
Keyword(s):  
Cervical Cancer ◽  
Health Care Organizations ◽  
Treatment Options ◽  
Personal Communication ◽  
Cervical Cytology ◽  
Middle Income ◽  
Screening Programs ◽  
Low Resource ◽  
Middle Income Countries ◽  
Cytology Screening

Context.—Cervical cancer remains the most common malignancy in women living in low- and middle-income countries, despite the decline of the disease in countries where cervical cytology screening programs have been implemented. Objectives.—To review the current incidence of cervical cancer in low-resource countries, the availability and types of screening programs, and the treatment options. Data Sources.—Literature review through PubMed, Internet search, and personal communication. Conclusions.—Although data are incomplete, available figures confirm that the rate of cervical cancer deaths and the availability of cervical cancer screening programs are inversely proportional and vary, in general, by the wealth of the nation. Despite the success of cervical cytology screening, many major health care organizations have abandoned screening by cytology in favor of direct visualization methods with immediate treatment of lesions by cryotherapy provided by trained, nonmedical personnel.

scholarly journals Prevalence, Types, and Factors of HPV Infection Among Women With Abnormal Cervical Cytology Screening at Ramathibodi Hospital

2021 ◽  
Vol 44 (3) ◽  
pp. 12-19
Author(s):  
Nithitda Boonthum ◽  
Somsak Suthutvoravut
Keyword(s):  
Cervical Cancer ◽  
Screening Program ◽  
Cervical Screening ◽  
Hpv Infection ◽  
Cervical Cytology ◽  
Single Infection ◽  
Pcr Analysis ◽  
Abnormal Cytology ◽  
Abnormal Cervical Cytology ◽  
Cytology Screening

Background: Cervical cancer is the second leading cancer among Thai women. Human papillomavirus (HPV) is the most common cause of cervical cancer. HPV16 and HPV18 are the most prevalence types in women with cervical cancer. Objectives: To study the prevalence and types of HPV infection and its associated risk factors among women with abnormal cervical cytology screening. Methods: This cross-sectional study purposively recruited 376 women who had abnormal cervical cytology screening by liquid-based cytology at the outpatient clinic, Ramathibodi Hospital from August 2015 until March 2016. HPV genotyping was done by the polymerase chain reaction (PCR). Analysis of the personal characteristics was done using descriptive statistics. Results: The prevalence of HPV infection was 41.5%. Among them, a single infection was found in 78.8% of women. The most common genotypes were HPV16 (8.5%) and HPV52 (7.7%). But HPV18 was found in only 1.9%. The characteristic which was significantly associated with HPV infection was age, nulliparity, and high-graded dysplasia (P < .05). Conclusions: High prevalence rate of HPV infection was found among women with abnormal cytology. High-risk HPV prevalence and type distribution may be useful for public health authorities in assessing the cervical screening program.  

scholarly journals HPV-related disease in Indigenous health

2009 ◽  
Vol 30 (5) ◽  
pp. 204
Author(s):  
Suzanne M Garland
Keyword(s):  
Cervical Cancer ◽  
Indigenous Health ◽  
Cervical Cytology ◽  
Precursor Lesions ◽  
High Quality ◽  
Screening Programs ◽  
Target Populations ◽  
Related Disease ◽  
Common Cancer ◽  
Cytology Screening

Cervical cancer is the second most common cancer in women worldwide, with the majority of cases occurring in the developing world. With effective high-quality cervical cytology screening programs, with wide coverage of target populations, precursor lesions can be detected and treated, ultimately preventing progression to the development of cervix cancer.

scholarly journals The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study

2019 ◽  
Vol Volume 13 ◽  
pp. 3419-3424 ◽  
Author(s):  
Jiangtao Yu ◽  
Ziwen Xu ◽  
Anyang Li ◽  
Jindi Zhang ◽  
Yi Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Efficacy And Safety ◽  
Recurrent Cervical Cancer

Role of Cervical Cytology in Surveillance after a Radical Trachelectomy in Patients with a Prior History of Cervical Cancer

2016 ◽  
Vol 143 (1) ◽  
pp. 204-205
Author(s):  
J.S. Shah ◽  
A.J. Brown ◽  
N.D. Fleming ◽  
A.M. Nick ◽  
P.T. Soliman ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cervical Cytology ◽  
Prior History ◽  
Radical Trachelectomy ◽  
History Of

scholarly journals Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study

2021 ◽  
Vol 13 ◽  
pp. 175883592110109
Author(s):  
Binhua Dong ◽  
Huachun Zou ◽  
Xiaodan Mao ◽  
Yingying Su ◽  
Hangjing Gao ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cohort Study ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Cox Regression ◽  
Intraepithelial Neoplasia ◽  
Population Based ◽  
Hpv Genotyping ◽  
Cytology Screening

Background: China’s Fujian Cervical Pilot Project (FCPP) transitioned cervical cancer screening from high-risk human papillomavirus (HR-HPV) nongenotyping to genotyping. We investigated the clinical impact of this introduction, comparing performance indicators between HR-HPV genotyping combined with cytology screening (HR-HPV genotyping period) and the previous HR-HPV nongenotyping combined with cytology screening (HR-HPV nongenotyping period). Methods: A retrospective population-based cohort study was performed using data from the FCPP for China. We obtained data for the HR-HPV nongenotyping period from 1 January 2012 to 31 December 2013, and for the HR-HPV genotyping period from 1 January 2014 to 31 December 2016. Propensity score matching was used to match women from the two periods. Multivariable Cox regression was used to assess factors associated with cervical intraepithelial neoplasia of grade 2 or worse (CIN2+). The primary outcome was the incidence of CIN2+ in women aged ⩾25 years. Performance was assessed and included consistency, reach, effectiveness, adoption, implementation and cost. Results: Compared with HR-HPV nongenotyping period, in the HR-HPV genotyping period, more CIN2+ cases were identified at the initial screening (3.06% versus 2.32%; p < 0.001); the rate of colposcopy referral was higher (10.87% versus 6.64%; p < 0.001); and the hazard ratio of CIN2+ diagnosis was 1.64 (95% confidence interval, 1.43–1.88; p < 0.001) after controlling for health insurance status and age. The total costs of the first round of screening (US$66,609 versus US$65,226; p = 0.293) were similar during the two periods. Higher screening coverage (25.95% versus 25.19%; p = 0.007), higher compliance with age recommendations (92.70% versus 91.69%; p = 0.001), lower over-screening (4.92% versus 10.15%; p < 0.001), and reduced unqualified samples (cytology: 1.48% versus 1.73%, p = 0.099; HR-HPV: 0.57% versus 1.34%, p < 0.001) were observed in the HR-HPV genotyping period. Conclusions: Introduction of an HR-HPV genotyping assay in China could detect more CIN2+ lesions at earlier stages and improve programmatic indicators. Evidence suggests that the introduction of HR-HPV genotyping is likely to accelerate the elimination of cervical cancer in China.

Sign in / Sign up

Export Citation Format

Share Document